Kyorin Licenses Merck’s OAB Drug Vibegron For Japan
This article was originally published in PharmAsia News
Executive Summary
Kyorin Pharmaceuticals has entered into a licensing agreement with U.S.-based Merck & Co for the overactive bladder drug vibegron, hoping to expand its product lineup in the urology field.
You may also be interested in...
Asia Deal Watch: Vibegron’s Vagabond Journey Continues With Eisai Acquiring Partial Asian Rights
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
US Supply Chain In Brief: White House Aims To Deliver With Block Stowing And Industrial Base Expansion
Biden administration works to expedite medical supplies and expand medical countermeasures production, while US FDA's DSCSA anti-counterfeiting paperwork burden estimate surges.
Care Needed With Plain Language Summaries Of EU Study Results
The EU will make it mandatory for clinical trial sponsors to prepare layperson summaries of their study results. Industry practices around content presentation, translation and dissemination of these documents will be keenly watched.